Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease
Status:
Completed
Trial end date:
2018-11-07
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate safety, efficacy, and tolerability of
treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in adults on dialysis for end
stage renal disease (ESRD) with chronic hepatitis C virus (HCV) infection of any genotype.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir